Literature DB >> 7690522

A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol.

B K Burton1, G S Prins, M S Verp.   

Abstract

OBJECTIVE: Our purpose was to prospectively evaluate the effectiveness of prenatal screening for Down syndrome by means of multiple serum markers. STUDY
DESIGN: alpha-Fetoprotein, human chorionic gonadotropin, and unconjugated estriol were measured in 8233 midtrimester serum samples, including 7492 from women < 35 years old and 741 from women > or = 35 years old. Down syndrome risks were computed by means of age and all three markers. Further testing was recommended for patients with a risk > or = 1:270. Testing for trisomy 18 was recommended for patients with an alpha-fetoprotein < or = 0.70 multiples of the median, human chorionic gonadotropin < or = 0.50 multiples of the median, and unconjugated estriol < or = 0.55 multiples of the median.
RESULTS: Of women screened initially 10.4% had a Down syndrome risk > or = 1:270; 10 of 12 known cases of Down syndrome were identified. One abnormality was detected for every 33 amniocenteses performed in this group. Of 0.4% of patients at increased risk for trisomy 18, two cases of trisomy 18 and one of triploidy were found.
CONCLUSION: Multiple marker screening is effective in identifying the majority of fetal chromosome anomalies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690522     DOI: 10.1016/0002-9378(93)90613-n

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  Trade-offs in prenatal detection of Down syndrome.

Authors:  M Serra-Prat; P Gallo; A J Jovell; M Aymerich; M D Estrada
Journal:  Am J Public Health       Date:  1998-04       Impact factor: 9.308

2.  Six year survey of screening for Down's syndrome by maternal age and mid-trimester ultrasound scans.

Authors:  D T Howe; R Gornall; D Wellesley; T Boyle; J Barber
Journal:  BMJ       Date:  2000-03-04

3.  Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening.

Authors:  Chanane Wanapirak; Wirawit Piyamongkol; Supatra Sirichotiyakul; Fuanglada Tongprasert; Kasemsri Srisupundit; Suchaya Luewan; Kuntharee Traisrisilp; Phudit Jatavan; Theera Tongsong
Journal:  BMC Health Serv Res       Date:  2019-11-27       Impact factor: 2.655

Review 4.  Beyond Trisomy 21: Additional Chromosomal Anomalies Detected through Routine Aneuploidy Screening.

Authors:  Amy Metcalfe; Catriona Hippman; Melanie Pastuck; Jo-Ann Johnson
Journal:  J Clin Med       Date:  2014-04-08       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.